121 related articles for article (PubMed ID: 38564431)
1. Self-Assembling Sulfated
Zhang S; Fan W; Ding C; Zhang M; Liu S; Liu W; Tang Z; Huang C; Yan L; Song S
ACS Appl Mater Interfaces; 2024 Apr; 16(15):18591-18607. PubMed ID: 38564431
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine.
Atalis A; Keenum MC; Pandey B; Beach A; Pradhan P; Vantucci C; O'Farrell L; Noel R; Jain R; Hosten J; Smith C; Kramer L; Jimenez A; Ochoa MA; Frey D; Roy K
J Control Release; 2022 Jul; 347():476-488. PubMed ID: 35577151
[TBL] [Abstract][Full Text] [Related]
3. Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses.
Qiao Y; Zhan Y; Zhang Y; Deng J; Chen A; Liu B; Zhang Y; Pan T; Zhang W; Zhang H; He X
Front Immunol; 2022; 13():992062. PubMed ID: 36569949
[TBL] [Abstract][Full Text] [Related]
4. Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern.
Renner TM; Akache B; Stuible M; Rohani N; Cepero-Donates Y; Deschatelets L; Dudani R; Harrison BA; Baardsnes J; Koyuturk I; Hill JJ; Hemraz UD; Régnier S; Lenferink AEG; Durocher Y; McCluskie MJ
Front Immunol; 2023; 14():1182556. PubMed ID: 37122746
[TBL] [Abstract][Full Text] [Related]
5. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
6. Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2.
Gale EC; Powell AE; Roth GA; Meany EL; Yan J; Ou BS; Grosskopf AK; Adamska J; Picece VCTM; d'Aquino AI; Pulendran B; Kim PS; Appel EA
Adv Mater; 2021 Dec; 33(51):e2104362. PubMed ID: 34651342
[TBL] [Abstract][Full Text] [Related]
7. Positively Charged-Amylose-Entangled Au-Nanoparticles Acting as Protein Carriers and Potential Adjuvants to SARS-CoV-2 Subunit Vaccines.
Fan B; Gu J; Deng B; Guo W; Zhang S; Li L; Li B
ACS Appl Mater Interfaces; 2023 Jun; 15(25):29982-29997. PubMed ID: 37330942
[TBL] [Abstract][Full Text] [Related]
8. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
[TBL] [Abstract][Full Text] [Related]
10. A-910823, a squalene-based emulsion adjuvant, induces T follicular helper cells and humoral immune responses
Yoshioka Y; Kobiyama K; Hayashi T; Onishi M; Yanagida Y; Nakagawa T; Hashimoto M; Nishinaka A; Hirose J; Asaoka Y; Tajiri M; Hayata A; Ishida S; Omoto S; Nagira M; Ishii KJ
Front Immunol; 2023; 14():1116238. PubMed ID: 36891311
[TBL] [Abstract][Full Text] [Related]
11. Protection from COVID-19 disease in hamsters vaccinated with subunit SARS-CoV-2 S1 mucosal vaccines adjuvanted with different adjuvants.
Sui Y; Andersen H; Li J; Hoang T; Bekele Y; Kar S; Lewis MG; Berzofsky JA
Front Immunol; 2023; 14():1154496. PubMed ID: 37020550
[TBL] [Abstract][Full Text] [Related]
12. Toll-like Receptor-4 (TLR4) Agonist-Based Intranasal Nanovaccine Delivery System for Inducing Systemic and Mucosal Immunity.
Bakkari MA; Valiveti CK; Kaushik RS; Tummala H
Mol Pharm; 2021 Jun; 18(6):2233-2241. PubMed ID: 34010002
[TBL] [Abstract][Full Text] [Related]
13. A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.
Steinbuck MP; Seenappa LM; Jakubowski A; McNeil LK; Haqq CM; DeMuth PC
Sci Adv; 2021 Feb; 7(6):. PubMed ID: 33547083
[TBL] [Abstract][Full Text] [Related]
14. An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters.
Tabynov K; Solomadin M; Turebekov N; Babayeva M; Fomin G; Yadagiri G; Renu S; Yerubayev T; Petrovsky N; Renukaradhya GJ; Tabynov K
Sci Rep; 2023 Jul; 13(1):12115. PubMed ID: 37495639
[TBL] [Abstract][Full Text] [Related]
15. Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant.
Gray LT; Raczy MM; Briquez PS; Marchell TM; Alpar AT; Wallace RP; Volpatti LR; Sasso MS; Cao S; Nguyen M; Mansurov A; Budina E; Watkins EA; Solanki A; Mitrousis N; Reda JW; Yu SS; Tremain AC; Wang R; Nicolaescu V; Furlong K; Dvorkin S; Manicassamy B; Randall G; Wilson DS; Kwissa M; Swartz MA; Hubbell JA
Biomaterials; 2021 Nov; 278():121159. PubMed ID: 34634664
[TBL] [Abstract][Full Text] [Related]
16. RBD decorated PLA nanoparticle admixture with aluminum hydroxide elicit robust and long lasting immune response against SARS-CoV-2.
Meena J; Singhvi P; Srichandan S; Dandotiya J; Verma J; Singh M; Ahuja R; Panwar N; Wani TQ; Khatri R; Siddiqui G; Gupta A; Samal S; Panda AK
Eur J Pharm Biopharm; 2022 Jul; 176():43-53. PubMed ID: 35589003
[TBL] [Abstract][Full Text] [Related]
17. Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration.
Xiao L; Yu W; Shen L; Yan W; Qi J; Hu T
ACS Appl Mater Interfaces; 2023 Aug; 15(30):35895-35905. PubMed ID: 37466148
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
19. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines.
Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ
J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238
[TBL] [Abstract][Full Text] [Related]
20. Broad and Durable Humoral Responses Following Single Hydrogel Immunization of SARS-CoV-2 Subunit Vaccine.
Ou BS; Saouaf OM; Yan J; Bruun TUJ; Baillet J; Zhou X; King NP; Appel EA
Adv Healthc Mater; 2023 Nov; 12(28):e2301495. PubMed ID: 37278391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]